Literature DB >> 19259310

At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?

Rotonya McCants Carr1, John P Lynch.   

Abstract

Entities:  

Year:  2008        PMID： 19259310      PMCID： PMC2632553     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  17 in total

1.  Lymph node metastases of gastric cancer. General pattern in 1931 patients.

Authors:  K Maruyama; P Gunvén; K Okabayashi; M Sasako; T Kinoshita
Journal:  Ann Surg       Date:  1989-11       Impact factor: 12.969

2.  A new weapon for attacking tumor blood vessels.

Authors:  Gregg L Semenza
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

3.  Classification of adenocarcinoma of the oesophagogastric junction.

Authors:  J R Siewert; H J Stein
Journal:  Br J Surg       Date:  1998-11       Impact factor: 6.939

4.  The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction.

Authors:  S M Dresner; P J Lamb; M K Bennett; N Hayes; S M Griffin
Journal:  Surgery       Date:  2001-01       Impact factor: 3.982

5.  Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

Authors:  Tomislav Dragovich; Sheryl McCoy; Cecilia M Fenoglio-Preiser; Jiang Wang; Jacqueline K Benedetti; Amanda F Baker; Christopher B Hackett; Susan G Urba; Ken S Zaner; Charles D Blanke; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

6.  Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

Authors:  Maarten L Janmaat; Mariëlle I Gallegos-Ruiz; José A Rodriguez; Gerrit A Meijer; Walter L Vervenne; Dick J Richel; Cees Van Groeningen; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

Review 7.  Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.

Authors:  Sjoerd M Lagarde; Fiebo J W ten Kate; Johannes B Reitsma; Olivier R C Busch; J Jan B van Lanschot
Journal:  J Clin Oncol       Date:  2006-09-10       Impact factor: 44.544

8.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

Review 9.  Multidisciplinary management of gastric and gastroesophageal cancers.

Authors:  Markus Moehler; Orestis Lyros; Ines Gockel; Peter-R Galle; Hauke Lang
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

10.  Crossroads in the combined-modality management of gastroesophageal junction carcinomas.

Authors:  Smith Apisarnthanarax; Joel E Tepper
Journal:  Gastrointest Cancer Res       Date:  2008-09
View more
  3 in total

1.  Proximal gastrectomy with jejunal interposition and TGRY anastomosis for proximal gastric cancer.

Authors:  Ping Zhao; Shuo-Meng Xiao; Ling-Chao Tang; Zhi Ding; Xiang Zhou; Xiao-Dong Chen
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

2.  Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.

Authors:  Petra Ganschow; Lena Hofmann; Sebastian Stintzing; Volker Heinemann; Martin Angele; Jens Werner; Christoph Schulz
Journal:  J Gastrointest Surg       Date:  2020-02-10       Impact factor: 3.452

3.  Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.

Authors:  Joseph A Miccio; Oluwadamilola T Oladeru; Jie Yang; Yaqi Xue; Minsig Choi; Yue Zhang; Hannah Yoon; Samuel Ryu; Alexander M Stessin
Journal:  J Gastrointest Oncol       Date:  2016-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.